Stephens & Co. Reiterates Overweight on West Pharmaceutical Servs, Maintains $360 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 69.5%

Neg 0% Neu 69.5% Pos 0%

Stephens & Co. analyst Steven Etoch reiterates West Pharmaceutical Servs (NYSE:WST) with a Overweight and maintains $360 price target.